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Prognostic significance of the bcl2 apoptotic family of
proteins in primary and recurrent cervical cancer
RAF Crawford, C Caldwell, RK lies, D Lowe, JH Shepherd and T Chard
St. Bartholomew's Hospital, London, UK
bcl-2 is one of a family of genes that control the apoptotic threshold of a cell. bcl-2 protein and its anti-apoptotic homologue, mcl-1, with the
pro-apoptotic protein, bax, are thought to function by forming homo- and heterotypic dimers that then control the progression to apoptosis.
p53 is also involved as a down-regulator of bcl-2 and a promoter of bax. To determine the effect of these apoptotic mechanisms, we used
immunohistochemistry to determine the prognostic significance of the expression of bcl-2, mcl-1, bax and p53 in primary and recurrent
cervical cancer. Tissues from 46 patients with primary cervical cancer and 28 women with recurrent carcinoma were stained for bcl-2, mcl-1,
bax and p53. Kaplan-Meier survival analysis was performed using the log-rank test for differences between groups. In the primary disease
group, positive staining for bcl-2 was associated with a better 5-year survival (bcl-2 +ve, 84% vs bcl-2 -ve, 53%, P = 0.03). Positive staining
for p53 was associated with a survival disadvantage (p53 +ve, 4-year survival 38% vs p53 -ve, 4-year survival 78%, P= 0.02). mcl-1 and bax
staining were not useful as prognostic indicators in primary disease. No marker was prognostic in recurrent disease. Positive bcl-2 staining
defines a group of patients with primary disease with a good prognosis. p53, an activator of the bax promoter, identifies a group with a worse
outcome. In recurrent disease, none of the markers reflected prognosis.
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The process of carcinogenesis may be associated with increased
stimulation of cell growth, loss of growth suppression, alterations
in immune surveillance and changes in apoptosis. The bcl-2 gene,
located on chromosome 18, encodes a 25-kDa protein that is local-
ized to the mitochondria, smooth endoplasmic reticulum and
perinuclear membrane (Hockenberry et al, 1990). bcl-2 has been
found to prevent apoptosis (programmed cell death) instead of
promoting cell proliferation and thus represents a new class of
oncogenes (Yang and Korsmeyer, 1996).
All mammalian cells express several cell death proteases such
as the bcl-2 family of cell death regulators, even when they are not
undergoing apoptosis (Vaux and Strasser, 1996). Overexpression
of bcl-2 specifically prevents cells from initiating apoptosis in
response to a number of stimuli, whereas it has little or no ability
to promote cell cycle progression or cell proliferation. The ability
of bcl-2 to inhibit apoptosis is dependent on expression of bcl-2
and on the formation of hetero- and homodimers between
members of the bcl-2 family (Yang et al, 1995; Kernohan and Cox,
1996). In vivo, bcl-2 associates with a 21-kDa protein known as
bax (bcl-2-associated protein X), with which it shares extensive
amino acid homology. Oltvai et al (1993) demonstrated that bcl-2
forms heterodimers with bax. The bax-bax homodimer favours
cell death, whereas the bax-bcl-2 heterodimer promotes cell
viability. The mcl-I gene (myeloid cell leukaemia-l) encodes a 37-
kDa protein that has significant homology with bcl-2. Like bcl-2,
it can partially abrogate apoptosis by blocking bax, although
weaker in action. mcl- 1 has been localized to the upper layer of the
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stratified squamous epithelium (Krajewski et al, 1994, 1995). mcl-
I and bcl-2 are expressed at different stages of differentiation in
many normal tissues.
p53, located on chromosome 17, encodes a 53-kDa protein that is
involved in cell growth regulation. In addition, p53 can induce apo-
ptosis in some cells and can down-regulate bcl-2 (Miyashita et al,
1994). Induction ofp53 alone is insufficient to trigger apoptosis but it
can increase the sensitivity of the tumour cells to apoptosis induced
by DNA damage. DNA damage leads to increased p53 expression.
In addition, p53 can activate the bax promoter, thus shifting the
bcl-2-bax ratio to a state of bax excess, favouring apoptosis.
Expression of bcl-2 is associated with better survival in patients
with solid tumours. There appears to be an inverse relationship
between p53 and bcl-2 expression in breast cancer (Haldar et al,
1994), ovarian cancer (Henriksen et al, 1995) and lymphoma
(Nguyen et al, 1996). This suggests an interaction between these
two factors in the regulation of programmed cell death. Several
studies have examined the role of bcl-2 either alone (Tjalma et al,
1997) or in conjunction with bax (Uehara et al, 1995) in cervical
cancer. Tjalma et al (1997) demonstrated a survival advantage for
bcl-2-positive patients, whereas Uehara et al (1995) showed no
prognostic significance of either bcl-2 or bax staining.
The objective of this study was to examine the prognostic
significance of immunohistochemical detection of the bcl-2 family
of apoptotic proteins (bcl-2, mcl-I and bax) and p53 in primary
and recurrent cervical cancer.
MATERIALS AND METHODS
The patients were a consecutive group of women attending the
gynaecological oncology units at St. Bartholomew's and The
Royal Marsden Hospitals, London, from January 1990 until
September 1992. Local Ethics Committees' permission was given
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Table 1 Conditions for individual antibodies
Protein Antibody Dilution and Antigen Control Staining
exposure pretreatment
bcl-2a Dako 124 mouse MC 1/50 40 min Pressure cooking Tonsil; internal Cytoplasmic
mcl-1 Pharmingen rabbit PC 13656E 1/2000 overnight Pressure cooking Tonsil; internal Cytoplasmic
bax Santa Cruz N20 rabbit PC 1/500 overnight None Tonsil; internal Cytoplasmic
p53* Dako DO-7 mouse MC 1/100iovernight None Breast Nuclear
aAntibodies in daily routine use in the diagnostic laboratory. MC, monoclonal; PC, polyclonal.
Table 2 Staining results of the tumours from patients with primary and
recurrent cervical cancer
Antibody/scoring Primary disease Recurrent disease
n = 44 (%) n = 29 (%)
bcl-2 -ve 10 (23) 19 (65)
bcl-2 < 10% 19 (43) 4 (14)
bcl-2 11-30% 7 (16) 2 (7)
bcl-2 31-50% 2 (4) 0
bcl-2 > 51% 6 (14) 4 (14)
mcl-1 -ve 1 (2) 0
mcl-1 < 10% 0 0
mcl-1 11-30% 1 (2) 1 (4)
mcl-1 31-50% 5 (11) 1 (4)
mcl-1 51-70% 12 (27) 5 (17)
mcl-1 > 71% 25 (57) 21 (75)
bax -ve 2 (4) 0
bax < 10% 11 (24) 3 (10)
bax 11-30% 12 (26) 7 (24)
bax 31-50% 4 (9) 5 (17)
bax 51-70% 8 (17) 5 (17)
bax > 71% 9 (20) 9 (31)
p53 -ve 28 (64) 15 (52)
p53 < 10 nuclei 1 (2) 5 (17)
p53 10 + nuclei(' 5%) 8 (18) 6 (21)
p53 > 5% 7 (16) 3 (10)
for the research relating to the immunohistochemical analysis of
the archival material and its correlation with survival data.
Fifty-seven women with primary disease and 42 women with
recurrent disease were recorded. The median age of the primary
group was 43 years and the median age of the recurrent group was
45 years. The median follow-up of women with primary disease
was 35 months (range 1-74 months). The 5-year survival of the
primary cancer group was 59% with the median follow-up not yet
reached. The median survival of women with recurrent cervical
cancer was 22 months from initial diagnosis (range 2-149
months). In the primary group, there were 28 women with FIGO
stage I disease, 11 with stage II disease, ten with stage III disease,
five with stage IV disease and no stage was recorded in three
cases. The pathology in 36 women was squamous-cell carcinoma,
adenocarcinoma in eight cases, adenosquamous carcinoma in nine
cases and not recorded in four cases. In the recurrent group, 19
patients initially had a stage I lesion, 13 had stage II disease, five
had stage III disease, four had stage IV disease and no stage was
recorded in one case. The pathology in 30 women was squamous-
cell carcinoma, adenocarcinoma in six cases, adenosquamous
carcinoma in five cases and not recorded in one case.
Sections (3 ,um) of cervical cancer were dewaxed and endogenous
peroxidase activity was blocked with 1.5% hydrogen peroxide in
methanol.
Table 3 Fisher's exact probability of an association between any two
markers
Primary/recurrent bcl-2 mcl-1 bax p53
bcl-2 0.26 0.15 0.66
mcl-1 0.28 0.62 0.6
bax 0.23 0.26 0.45
p53 0.32 0.25 0.38
The results for primary disease are shown above and to the right of the
diagonal, whereas results for recurrent disease are shown below and to the
left of the diagonal.
The pressure cooker antigen retrieval system was used for the
bcl-2 and mcl-I antibodies (Norton et al, 1994). The primary anti-
body was added at the appropriate dilution (Table 1) and then incu-
bated. The immunohistochemical procedure in this study used the
avidin-biotin complex method (Hsu et al, 1981) using Vectastain®
Universal Elite ABC kit (Vector Laboratories, Burlingame, CA,
USA). The appropriately diluted primary antibody was labelled
with a biotinylated secondary antibody. This was then coupled
with a preformed avidin horseradish peroxidase complex and visu-
alized with chromogen diaminobenzidine tetrahydrochloride.
Appropriate positive controls were used as detailed in Table 1. The
primary antibody was omitted for the negative control.
All slides were evaluated for immunostaining without knowl-
edge of the clinical outcome. Sections were scored by determining
the proportion of stained cells relative to the overall number of
tumour cells, excluding those in areas of necrosis. p53 was scored
in four categories: negative; fewer than ten nuclei positive; more
than ten nuclei positive but less than 5% of the whole tumour posi-
tive; and more than 5% of the whole tumour positive. This type of
scoring included two different ways of expressing positivity, i.e.
absolute numbers of positive cells and percentage positivity,
reflecting the scoring systems in published work. bcl-2 was scored
in five categories: negative; less than 10% of the tumour; 10-30%;
30-50%; and > 50%. bax and mcl- 1 had the same scoring system as
bcl-2 with an additional positive category of >70% staining. The
sections were scored independently (RAFC and CC). Disagreement
over score was found with less than 1Y0% of the slides examined
and consensus was reached on further review. Positive staining was
scored when the colour intensity was equivalent to the control. No
attempt was made to grade intensity in this study.
Statistical analysis
The percentage survival for each group was calculated using the
Kaplan-Meier method and comparisons between groups were
performed using the log-rank test (SPSS for Windows, 6.1.3
1995). When data did not extend to 5 years, survival rate is given
per years of follow-up in that group.
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Figure 1 bcl-2 staining and survival in primary cervical cancer.
Kaplan-Meier survival curves for patients with primary cervical cancer
stained with bcl-2 at a threshold of 10%. bcl-2 negative, n = 29, 13 events,
4-year survival 53%; bcl-2 positive, n = 15, two events, 4-year survival 84%,
P= 0.03. - - -, bcl-2 stain > 10%, n = 15;-, bcl-2 stain < 10%, n = 29
RESULTS
Suitable tissue for immunohistochemical analysis was available in
44 cases of primary cancer and 29 cases of recurrent cancer.
Details of the extent of staining for the antibodies are shown in
Table 2. bcl-2 positivity (> 10% of the tumour) was recorded in
34% (15/44) of primary and 21% (6/29) of recurrent tumours. mcl-
1 positivity (> 70% of the tumour) was recorded in 57% (25/44)
of primary and 75% (21/28) of recurrent cancers. bax staining
(> 50% of the tumour) was seen in 37% (17/46) of primary and
48% (14/29) of recurrent cancers. Using an absolute method of
scoring (more than ten nuclei positive), p53 was positive in 34%
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Figure 2 Graph showing survival associated with positive p53 nuclear
staining using an absolute threshold (> 10 nuclei positive). p53-negative
tumours, n = 29, six events, 4-year survival 78%; p53-positive tumours,
n = 15, nine events, 4-year survival 38%, P= 0.02. - - -, p53 stain positive,
n = 15; -, p53 stain < 10 nuclei positive, n = 29
(15/44) of primary and 31% (9/29) of recurrent tumours. Using the
semiquantitative measure of 5%, only 16% (7/44) of primary and
30% (3/10) of recurrent cancers were positive for p53.
The relationships between markers are shown in Table 3. There
was no significant association among bcl-2 and the other markers.
Analysis of the immunohistochemical markers with respect to
survival is shown in Table 4. bcl-2 positivity was prognostic of a
good outcome in primary disease (Figure 1), whereas this was not
significant in recurrent disease (P = 0.47). Neither mcl-1 nor bax
staining was prognostic of a survival advantage. Using the
threshold of ten nuclei positive, p53 was a significant prognostic
Table 4 Survival statistics for immunohistochemical markers in primary and recurrent cervical cancers
Primary disease Recurrent disease
Antibody Number of cases; P-value Number of cases; P-value
events; log-rank events; log-rank
x2 x2d.f. = I survival
bcl-2 4.46 0.03 0.52 0.47
Staining < 10% n= 29; 13 events; n= 23; 19 events;
4 years, 53% median 8 months
Staining > 10% n= 15; two events; n = 4; four events;
4 years, 84% median 2 months
mcl-1 0.08 0.78 0.18 0.67
Staining < 70% n= 19; six events; n= 7; six events;
5 years, 61% median 8 months
Staining > 70% n = 25; nine events; n= 21; 19 events;
5 years, 63% median 8 months
bax 0.51 0.47 0.47 (at staining 0.49
threshold of 50%)
Staining < 70% n= 35; 11 events; n= 15; 12 events;
5 years, 66% median 8 months
Staining > 70% n= 9; four events; n = 14; 13 events;
5 years, 53% median 8 months
p53 5.84 0.02 2.36 0.12
< 10 nuclei positive n = 29; six events; n= 20; 16 events;
4 years, 78% median 8 months
> 10 nuclei positive n = 15; nine events; n = 9; nine events;
4 years, 38% median 3 months
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marker for poor outcome in primary disease (Figure 2). p53
showed a trend towards being a significant prognostic factor in
recurrent disease using this threshold. When using the semiquanti-
tative 5% threshold, there was no significant prognostic effect with
either the primary or the recurrent groups.
DISCUSSION
In this study, bcl-2-positive staining in the cervical carcinoma was
a significant prognostic factor in predicting survival in primary
cervical cancer: there was an 84% 4-year survival in bcl-2-positive
patients compared with a 53% 4-year survival in bcl-2-negative
patients (P = 0.03). This finding agrees with Tjalma et al (1997)
who found a survival advantage in patients with bcl-2 staining of
cervical carcinoma in surgically treated disease. Tjalma et al
(1998) found on multivariate analysis that survival could be
independently predicted by bcl-2 expression, FIGO stage and
lymphatic permeation of the tumour. Uehara et al ( 1995) found no
survival advantage with bcl-2 staining or any evidence of interac-
tion with bax in early-stage cervical cancer. However, in Uehara's
paper it was not clear what constituted a positive result; this factor
has a substantial bearing on the prognostic value of immunohisto-
chemistry.
The lack of prognostic value of mcl- 1 and bax is not surprising
when one considers the widespread nature of the staining seen
(mcl-l > 10%, 43/44; bax > 10%, 33/46). This reflects the biology
of the apoptotic proteins that are present in the cytoplasm even
when the cell is not undergoing apoptosis (Vaux and Strasser,
1996). These proteases can be activated without having to be
newly synthesized, and apoptosis can be induced without influ-
encing transcription from the protease genes. Also, individual bcl-
2 family members may have different apoptosis-triggering stimuli,
activating distinct cysteine proteases. There may be partial redun-
dancy between the activities of different proteases. Immuno-
histochemistry can detect proteins that are demonstrably present
but may be inactive in carcinogenesis.
p53 staining was a significant prognostic factor when using an
absolute method of scoring (P = 0.02), although Wynford-Thomas
(1992) pointed out that false-positive immunostaining may occur.
In addition, the antibody may detect the higher concentration of
normally active wild-type p53 needed for DNA repair in that
particular cell. It is, therefore, more appropriate to use the semi-
quantitative measure (at 5%), and to disregard the significant
results relating to survival for p53 as measured by a small number
of nuclei stained (< 5%). When a semiquantitative measure (> 5%)
was applied, the prognostic effect was not significant (P = 0.64),
which is similar to other reports (Hunt et al, 1996).
van Diest et al (1997) highlight the problems with scoring
immunohistochemistry and suggest a protocol to reduce the vari-
ability between published papers. In this study, we have used only
the defined staining pattern for each antibody, reviewed the
complete tumour on the section stained and used a cut-off deter-
mined by clinical parameters. van Diest et al (1997) suggest that,
in addition, the area of the lesion to be assessed and method of
sampling of fields of vision should be defined. Further influences
on the results of immunohistochemistry relating to tissue collec-
tion and processing can only be reduced when agreement relating
to protocols is reached.
In recurrent disease, there was no prognostic significance
associated with any of the markers. The recurrent group was
very heterogeneous, including patients with persistent disease
following primary treatment, true recurrence following a period of
remission and even patients who received inappropriate primary
treatment. This heterogeneity might explain why the apoptotic
proteins were of no value in predicting outcome.
HPV in cervical carcinoma has been extensively investigated
and is pivotal in the development of the cancer. In this study, in
excess of 90% of the tumours were virus positive (unpublished
results) similar to previous reports (Walboomers and Meijer,
1997). It is likely that HPV acts at an earlier point in carcinogen-
esis than the apoptotic proteins and, therefore, this immunohisto-
chemical study will not detect an interaction.
Saegusa et al (1995) examined the relationship between bcl-2,
bax and HPV expression. bcl-2 expression was greatest in CIN 3
compared with invasive carcinoma. However, as in the present
study, this was a cross-sectional study and it is not clear whether
those bcl-2-positive preinvasive cases would have progressed to
cancer or not without treatment. Twenty per cent of the carcinomas
in this study stained for bcl-2 and 40% for bax, similar to the
present study. There was no association among bcl-2, bax staining
and HPV status in the 60 squamous cancers examined.
There appeared to be no value in considering combinations of
staining characteristics. The relative ratios of the proteins are impor-
tant (Kemohan and Cox, 1996) and the methodology to determine
this needs to be further refined. However, on the basis of this study,
there does not appear to be any value in analysing the tumours with
the bank of immunohistochemical markers we proposed.
In conclusion, the identification of bcl-2 expression as deter-
mined by immunohistochemistry is a useful prognostic factor in
cervical cancer. Although bcl-2 prevents apoptosis, it is not clear
why this should then lead to a better outcome. The addition of
further immunohistochemical markers related to apoptosis does
not appear to be helpful, although the biology of the bcl-2 family
suggests that the interaction of pro- and anti-apoptotic factors
should be important.
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